Evidence map›Paper›PMID 29998877›Full record

ArticleThe Indian journal of medical research2018

Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study.

Vikas Gautam, Nusrat Shafiq, Johan W Mouton, Sameer Malhotra, Satinder Kaur, Pallab Ray

Open access · diamondAbstract read
In one paragraph

Article in The Indian journal of medical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.2field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Colistin: Lights and Shadows of an Older Antibiotic.Molecules (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Vikas GautamDepartment of Medical Microbiology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Nusrat ShafiqDepartment of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Johan W MoutonDepartment of Medical Microbiology & Infectious Diseases, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Sameer MalhotraDepartment of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Satinder KaurDepartment of Medical Microbiology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Pallab RayDepartment of Medical Microbiology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Post Graduate Institute of Medical Education and Research · INErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & objectives: There is little information concerning intravenously (i.v.) administered colistin in patients with multidrug-resistant (MDR) Gram-negative infections. Thus, this pilot prospective study was undertaken to characterize efficacy and pharmacokinetics of colistin in patients with MDR Gram-negative infections. Methods: Nine patients with age >12 yr and MDR Gram-negative infections were included, of whom six were given colistin at the doses of 2 MU, while three patients were given 1 MU i.v. dose every 8 h. Blood samples were collected at different time intervals. Determination of colistin concentration was done by a ultra-high-performance liquid chromatography/mass spectrometry/selected reaction monitoring assay. Results: The area under the plasma concentration-versus-time curve over eight hours (AUC Interpretation & conclusions: As there is a paucity of information on AUC/MIC for colistin, it may not be possible to conclude whether AUC/MIC values in our patients were adequate. There is a microbiological clearance of organism, which goes in favour of the dosing schedule being adequate. Further studies need to be done to understand the pharmacokinetics of colistin in patients with infections.

Indexed as

Drug Resistance, Multiple, BacterialAnti-Bacterial AgentsColistinGram-Negative Bacterial InfectionsHumansPilot ProjectsProspective StudiesAnti-Bacterial AgentsColistinColistin - Gram-negative infections - MDR - pharmacodynamics - pharmacokinetics

Identifiers

PMID29998877
PMCPMC6057249
OpenAlexW2812189285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.